TGR5, the bile acid receptor, as a negative regulator of the NF-κB and AKT pathway, may effectively inhibit the progression of non-small cell lung cancer (NSCLC) [45]. The gene discussed is GPBAR1; the disease is non-small cell lung carcinoma.